Trial 4K-16-1


A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) in Combination with Axitinib (INLYTA®) versus Sunitinib (SUTENT®) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

Type: Treatment
Phase: Phase III
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Immunotherapy
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Varsha Tulpule, M.D.
Other Trial Staff:  Cheryl Kefauver, Coordinator, Victoria Banerjee, Coordinator, Aleksei Belousov, Coordinator, Lagrimas Ilagan, D.M., Roberto Tejada, D.M., Taison Tran, Coordinator, Charis Barg, Coordinator, Bartolo Santos, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.